Asset
Ficerafusp Alfa
Bicara Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04429542 | phase1 | recruiting | 2020-06-01 | 2026-12-31 | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.